A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath, S.; Barlogie, B.; Berenson, J.; Siegel, D.; Irwin, D.; Richardson, P. G.; Niesvizky, R.; Alexanian, R.; Limentani, S. A.; Alsina, M.; Adams, J.; Kauffman, M.; Esseltine, D.-L.; Schenkein, D. P.; Anderson, K. C.; British Journal of Haematology, 2004, vol. 127, issue 2, p 165, ISSN 00071048. ISBN 00071048.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef